Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device Commercial Deals

The Illumina Shareholder Votes Are In, And Nobody Got What They Wanted

  • News

Executive Summary

Carl Icahn was successful in ousting Illumina’s chair, however its CEO, Francis deSouza remains. Both analysts and investors believe this could further encourage Illumina to divest Grail.

You may also be interested in...



Minute Insight: Illumina Seeks Stability, Names Thaysen As New CEO

The genome-sequencing giant has named Jacob Thaysen, who brings extensive experience from Agilent, as its new leader.

More Kerfuffle At Illumina. This Time, It Is Job Cuts

The company is shrinking its work force and real estate footprint in a bid to save money.

CEO Resignation Raises Doubts About Illumina’s Commitment To Grail

Francis deSouza resigned as CEO and chairman of Illumina just a few weeks after winning the support of shareholders. General counsel Charles Dadswell will take over as interim CEO.

Table

View full table

Related Content

In Vivo
Medtech Insight
Medtech Insight
Medtech Insight

Topics

Related Companies

Tags:
Medical Device Commercial Deals
Latest Headlines

Why Investing In ESG Measures Is Good For Medtech’s Health And Sustainability

IVD DNA Test For Cancer Receives New Regulatory Classification

Minute Insight: Medtronic May Sell Respiratory And Monitoring Units To Private Equity

Stakeholders Give FDA An Earful; Poor Communication, Recall Inefficiency, Patients At Risk

See All
UsernamePublicRestriction

Register

MT147954

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By